Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

This study is testing a combination of two drugs — furmonertinib (a targeted therapy) and bevacizumab (an anti-blood vessel drug) — given before surgery in patients with lung adenocarcinoma that has a specific EGFR mutation. The goal is to shrink the tumor enough to make surgery possible or more successful. **You may be eligible if...** - You have confirmed lung adenocarcinoma with an EGFR-sensitive mutation (identified by biopsy) - Your cancer is stage III or IVA and has not spread to distant organs - Surgery is potentially possible (either now or after treatment) - Your lung function is adequate and your ECOG score is 0 or 1 **You may NOT be eligible if...** - Your cancer has distant metastases (spread to other organs) - You are pregnant (must have negative test) - Your organ function does not meet the required levels Talk to your doctor to see if this trial is right for you.